According to Fortune Business Insights, the global Tuberculosis (TB) Diagnostics Market was valued at USD 2.40 billion in 2025 and is projected to grow from USD 2.53 billion in 2026 to USD 4.14 billion by 2034, exhibiting a CAGR of 6.33% during the forecast period. The increasing prevalence of tuberculosis, rising awareness of early disease detection, favorable government initiatives, and continuous advancements in rapid molecular diagnostic technologies are driving market expansion. Furthermore, growing investments in healthcare infrastructure, public-private partnerships, and the adoption of innovative diagnostic platforms are expected to accelerate the demand for tuberculosis diagnostic solutions worldwide.
Tuberculosis (TB) remains one of the world's most significant infectious diseases, affecting millions of people annually despite decades of global control efforts. Early and accurate diagnosis plays a critical role in reducing transmission, improving treatment outcomes, and preventing drug-resistant TB.
The tuberculosis (TB) diagnostics market has witnessed remarkable technological advancements in recent years, shifting from traditional smear microscopy to highly sensitive molecular diagnostic techniques. Governments, healthcare organizations, and diagnostic companies continue investing heavily in innovative testing solutions that deliver faster and more reliable results.
Increasing healthcare expenditure, expanding laboratory infrastructure, and growing awareness campaigns are expected to create favorable opportunities for market participants throughout the forecast period.
The increasing burden of tuberculosis worldwide continues to create substantial demand for advanced diagnostic technologies. Healthcare providers increasingly prefer rapid molecular diagnostics because they offer superior sensitivity, quicker turnaround time, and enhanced detection of drug-resistant TB strains.
International organizations such as WHO continue recommending molecular diagnostic testing as the preferred initial diagnostic approach for suspected tuberculosis cases. These recommendations are significantly accelerating global adoption.
Growing investments from public healthcare agencies and private diagnostic manufacturers are further strengthening the competitive landscape.
Despite improvements in healthcare systems, tuberculosis continues to affect millions globally. High disease prevalence in Asia Pacific, Africa, and parts of Eastern Europe continues to generate strong demand for efficient screening and diagnosis.
Governments are strengthening TB elimination programs by expanding diagnostic access in both urban and rural healthcare facilities.
Rapid molecular diagnostic technologies have transformed tuberculosis diagnosis by delivering highly accurate results within hours rather than weeks.
Compared to conventional culture-based methods, molecular diagnostics offer: